- Home
- BIRK vs BBIO Comparison
BIRK vs BBIO Comparison
Compare BIRK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRK
- BBIO
- Stock Information
- Founded
- BIRK 1774
- BBIO 2015
- Country
- BIRK United Kingdom
- BBIO United States
- Employees
- BIRK N/A
- BBIO N/A
- Industry
- BIRK
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BIRK
- BBIO Health Care
- Exchange
- BIRK Nasdaq
- BBIO Nasdaq
- Market Cap
- BIRK 8.8B
- BBIO 9.4B
- IPO Year
- BIRK 2023
- BBIO 2019
- Fundamental
- Price
- BIRK $50.13
- BBIO $53.38
- Analyst Decision
- BIRK Strong Buy
- BBIO Strong Buy
- Analyst Count
- BIRK 11
- BBIO 16
- Target Price
- BIRK $68.27
- BBIO $63.81
- AVG Volume (30 Days)
- BIRK 1.9M
- BBIO 2.4M
- Earning Date
- BIRK 08-14-2025
- BBIO 08-05-2025
- Dividend Yield
- BIRK N/A
- BBIO N/A
- EPS Growth
- BIRK 178.47
- BBIO N/A
- EPS
- BIRK 1.92
- BBIO N/A
- Revenue
- BIRK $2,380,334,704.00
- BBIO $235,812,000.00
- Revenue This Year
- BIRK $17.97
- BBIO $115.49
- Revenue Next Year
- BIRK $14.51
- BBIO $64.61
- P/E Ratio
- BIRK $26.11
- BBIO N/A
- Revenue Growth
- BIRK 17.60
- BBIO 7.62
- 52 Week Low
- BIRK $40.56
- BBIO $21.72
- 52 Week High
- BIRK $62.66
- BBIO $53.97
- Technical
- Relative Strength Index (RSI)
- BIRK 47.69
- BBIO 63.37
- Support Level
- BIRK $49.21
- BBIO $49.75
- Resistance Level
- BIRK $52.89
- BBIO $52.85
- Average True Range (ATR)
- BIRK 1.34
- BBIO 2.12
- MACD
- BIRK -0.13
- BBIO 0.18
- Stochastic Oscillator
- BIRK 21.30
- BBIO 91.76
About BIRK Birkenstock Holding plc
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.